Immphentiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11471400 HIKMA Phenylephrine hydrochloride ready-to-use solution
Aug, 2036

(12 years from now)

US11213480 HIKMA Phenylephrine hydrochloride ready-to-use solution
Sep, 2036

(12 years from now)

Immphentiv is owned by Hikma.

Immphentiv contains Phenylephrine Hydrochloride.

Immphentiv has a total of 2 drug patents out of which 0 drug patents have expired.

Immphentiv was authorised for market use on 20 December, 2012.

Immphentiv is available in solution;intravenous dosage forms.

The generics of Immphentiv are possible to be released after 26 September, 2036.

Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 December, 2012

Treatment: NA


More Information on Dosage

IMMPHENTIV family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic